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Geographic Variation in Health Service Use and Perceived Access Barriers for
Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy
Abstract
Objective. Rates of chronic non-cancer pain are increasing worldwide, with concerns regarding poorer
access to specialist treatment services in remote areas. The current study comprised the first in-depth
examination of use and barriers to access of health services in Australia according to remoteness.
Methods. A cohort of Australian adults prescribed pharmaceutical opioids for chronic non-cancer pain (n
= 1,235) were interviewed between August 2012 and April 2014, and grouped into 'major city' (49%), 'inner
regional' (37%), and 'outer regional/remote' (14%) according to the Australian Standard Geographical
Classification based on postcode. Multinomial logistic regression analyses were conducted to determine
geographical differences in socio-demographic and clinical characteristics, health service use, and
perceived barriers to health service access. Results. The 'inner regional group' and 'outer regional/remote
group' were more likely to be male (relative risk ratio (RRR)=1.38,95%CI 1.08-1.77 and RRR = 1.60, 95%CI
1.14-2.24) and have no private health insurance (RRR = 1.53, 95%CI 1.19-1.97 and RRR = 1.65, 95%CI
1.16-2.37) than the 'major city group' (49%). However, the 'inner regional group' reported lower pain
severity and better mental health relative to the 'major city group' = 0.92, 95%CI 0.86-0.98 and RRR = 1.02,
95%CI 1.01-1.03, respectively). Although rates of health service access were generally similar, the 'outer
regional/remote group' were more likely to report client-practitioner communication problems (RRR =
1.57, 95%CI 1.03-2.37), difficulties accessing specialists (RRR = 1.56, 95%CI 1.01-2.39), and perception of
practitioner lack of confidence in prescribing pain medication (RRR = 1.73, 1.14-2.62), relative to both
groups. Conclusion. Perceived communication, access, and financial barriers to healthcare indicate the
need for increased efforts to address geographic inequality in pain treatment.
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Abstract

28

Objective: Rates of chronic non-cancer pain are increasing worldwide, with concerns

29

regarding poorer access to specialist treatment services in remote areas. The current study

30

comprised the first in-depth examination of use and barriers to access of health services in

31

Australia according to remoteness.

32

Methods: A cohort of Australian adults prescribed pharmaceutical opioids for chronic non-

33

cancer pain (n=1,235) were interviewed between August, 2012 and April, 2014, and grouped

34

into ‘major city’ (49%), ‘inner regional’ (37%) and ‘outer regional/remote’ (14%) according

35

to the Australian Standard Geographical Classification based on postcode. Multinomial

36

logistic regression analyses were conducted to determine geographical differences in socio-

37

demographic and clinical characteristics, health service use, and perceived barriers to health

38

service access.

39

Results: The ‘Inner Regional group’ and ‘Outer Regional/Remote group’ were more likely to

40

be male (relative risk ratio (RRR)=1.38,95%CI 1.08-1.77 and RRR=1.60, 95%CI 1.14-2.24)

41

and have no private health insurance (RRR=1.53, 95%CI 1.19-1.97 and RRR=1.65, 95%CI

42

1.16-2.37) than the ‘Major City group’ (49%). However, the ‘Inner Regional group’ reported

43

lower pain severity and better mental health relative to the ‘Major City group’ =0.92, 95%CI

44

0.86-0.98 and RRR=1.02, 95%CI 1.01-1.03, respectively). Although rates of health service

45

access were generally similar, the ‘Outer Regional/Remote group’ were more likely to report

46

client-practitioner communication problems (RRR=1.57, 95%CI 1.03-2.37), difficulties

47

accessing specialists (RRR=1.56, 95%CI 1.01-2.39), and perception of practitioner lack of

48

confidence in prescribing pain medication (RRR=1.73, 1.14-2.62), relative to both groups.

49

Conclusion: Perceived communication, access and financial barriers to health care indicate

50

the need for increased efforts to address geographic inequality in pain treatment.

51

Keywords: chronic pain; healthcare; treatment; remote; policy; opioids
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Introduction

53
54

In Australia, chronic pain is estimated to affect nearly 20% of the adult population (2-5).

55

Chronic non-cancer pain (CNCP) reduces quality of life and impairs physical functioning,

56

sleep, mood, ability to work, and activities of daily living (e.g., walking, shopping) (6, 7),

57

with an estimated cost of AUD$34 billion nationally per annum in Australia (4). Treatments

58

that reduce pain severity and interference can mitigate some of these negative consequences

59

and reduce health care, societal and economic burden (6). The use of opioid pharmacotherapy

60

has increased in recent years, despite insufficient evidence for the effectiveness of long-term

61

opioid treatment for CNCP (8). Australia’s consumption of opioid analgesics was ranked 10th

62

globally in 2010, with higher rankings for specific analgesics (3rd and 5th for oxycodone and

63

morphine) (9). Behavioural, psychological and non-opioid pharmacotherapy treatments are

64

also available and demonstrate some efficacy in reducing pain (10-12). As such, current

65

guidelines typically emphasise a multi-disciplinary approach to treatment (13).

66
67

Despite the prevalence, recent data indicates that many people with CNCP are not able to

68

access specialist care either in Australia nor internationally, with concern that access

69

problems are amplified in remote geographical areas (14, 15). Higher rates of mortality and

70

morbidity are typically evident for those living in remote areas of Australia relative to those

71

living in urban areas (16). Whilst some self-report population-based studies show similar

72

rates of health service use across remoteness regions (17), analysis of routine administrative

73

data suggests fewer general practitioners and specialists available per capita, and lower rates

74

of health service use (with the notable exception of higher hospitalisation rates), in remote

75

areas (16) . Strategic action plans emphasise addressing these inequalities through updated

76

models of care and health service funding (15). To undertake such action, geographical
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variation in the experience of CNCP and treatment service access need to be understood, and

78

other factors which may impact on access (e.g., financial barriers, perceived quality of

79

services and treatments, beliefs regarding effects of medications, strategies for coping, level

80

of support) investigated. To date, such undertakings in Australia have generally been focused

81

only on a small sample within a single geographic region, as in the qualitative study by

82

Briggs et al. (18), who identified poor access to information and services and inadequate pain

83

management training as primary barriers to health service access for fourteen participants

84

with chronic low back pain in remote Western Australia.

85
86
87

As such, the aims of this paper are to:


Compare the socio-demographic and clinical profile of a cohort of adults Australians

88

with CNCP prescribed opioids by geographical remoteness classification (major

89

cities, inner and outer regional, remote and very remote locations);

90



classification amongst this cohort; and

91
92

Compare treatment and health service access according to geographical remoteness



Compare barriers to accessing treatment and services (e.g., financial considerations,

93

access and beliefs) according to geographical remoteness classification amongst this

94

cohort.

95

Geography, Healthcare and Chronic Pain
96

Methods

97

Design

98

The Pain and Opioids IN Treatment (POINT) study is a prospective cohort study of 1,514

99

persons in Australia prescribed opioids for CNCP (for a full description of the cohort

100

methodology, see Campbell et al. (19)). The data presented were collected via telephone

101

interview with a researcher, a self-complete survey and medication diary at baseline (August

102

2012 to April, 2014). The self-complete survey and medication diary were completed at

103

home in the week following the telephone interview.

104
105

Ethics

106

The study was approved by the UNSW Human Research Ethics Committee (#HC12149). The

107

study also received A1 National Pharmacy Guild Approval to approach pharmacists to assist

108

with recruitment (#815).

109
110

Eligibility Criteria

111

Inclusion criteria comprised: 18 year of age or older, competent in English; without apparent

112

memory or other cognitive impairment; living with CNCP (defined as pain present daily for a

113

minimum of three months); and currently prescribed a strong opioid classified as Schedule 8

114

of the Australian Uniform Scheduling of Medicines and Poisons (morphine, oxycodone,

115

fentanyl, buprenorphine, methadone, hydromorphone, and codeine phosphate as a single

116

ingredient) (20) and used this prescribed opioid for more than 6 weeks at the time of

117

admission in the cohort. Exclusion criteria comprised cases where Schedule 8 opioids were

118

prescribed for cancer pain or as opioid substitution therapy for heroin dependence.

119
120

Participants and Procedures
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From a database of 5,745 community pharmacies, 1,868 were willing to refer potentially

122

eligible participants (19). In total, 35% of pharmacies across all states and territories in

123

Australia agreed to participate. Of those potential participants who were referred (n=2,725),

124

1,873 were eligible, and a total of 1,514 completed the baseline POINT study interview (201

125

refused after being deemed eligible and 100 were unable to be contacted). Phone interviews

126

were conducted by research assistants who had a minimum 3-year health or psychology

127

degree. Interviewers had received training in the survey instrument and were provided

128

glossaries of chronic pain medications and conditions. Participants were included in the

129

analyses reported in this paper if they completed both the baseline telephone interview and

130

the self-complete measures including the medication diary (n=1,243); a further eight

131

participants were excluded as they did not provide their postcode (final sample n=1,235).

132
133

Measures

134

Full details of the measures administered in the study are reported elsewhere (19); brief

135

summaries of measures used in the current analyses are provided below.

136
137

Demographic and Clinical Characteristics

138

In addition to demographics, participants reported lifetime pain conditions and pain duration.

139

Participants also completed the Brief Pain Inventory short-form (BPI) (21), and current pain

140

severity and pain interference sub-scores were calculated. Physical and mental health

141

component scores from the SF-12 were calculated; scores were calculated according to

142

standard algorithms, with higher scores indicating better health (22). Depression and

143

generalised anxiety disorder were measured using the Patient Health Questionnaire (PHQ-9)

144

and the Generalised Anxiety Disorder (GAD-7) modules of the Patient Health Questionnaire

145

(23). Symptoms indicating moderate to severe depression were defined as a score of ≥10 on
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the PHQ-9 (24), symptoms of moderate to severe anxiety were defined as a score of ≥10 on

147

the GAD-7 (25). Post-traumatic stress disorder (PTSD) was measured using the Primary Care

148

PTSD screen (PC-PTSD); a score ≥ 3 was considered indicative of PTSD (26).

149
150

Treatment and Health Service Access

151

Participants were asked about past month prescribed use of pharmaceutical opioids and

152

duration of current continuous episode of opioid use. Oral morphine equivalent (OME) daily

153

doses were estimated using available references (27) based on self-reported opioid use in a

154

medication diary completed over a one week period (included in the self-complete

155

questionnaire mailed to participants). Participants reported the number of times they had used

156

certain health services (general practitioners, ambulance and emergency department services,

157

and hospital day procedures) in the past month. Participants were also asked about past

158

month use of health services directly related to pain, including physiotherapy, medical

159

specialist services, mental health services (i.e., psychiatrist, psychologist, and counsellor);

160

other physical therapies (i.e., massage, Osteopath, Yoga, Tai Chi, Feldenkrais, Pilates,

161

Supervised Exercise, Tens Machine and Bowen Therapy) and complementary and alternative

162

medicines (i.e., chiropractic services, support groups, acupuncture, vitamins and minerals).

163
164

Barriers to Treatment

165

Items assessing barriers to treatment were extracted from previous research (28), and then

166

modified based on feedback from the study’s chief investigators and advisory committee.

167

Participants were asked if they had ever experienced particular barriers (yes/no). Barriers

168

included being unable to get to a pharmacy or doctor, being unable to access specialist

169

advice, being unable to afford other types of medication and being unable to afford other

170

treatments (e.g., counselling, physiotherapy, and chiropractor).
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Medication Beliefs, Pain Self-Efficacy, Social Support and Alcohol and Other Drug Use

173

Medication beliefs were assessed by two subscales of the Beliefs about Medications

174

Questionnaire (BMQ) (29): the Specific-Necessity subscale, which assesses the participants’

175

beliefs about the necessity of their current medication, and the Specific-Concerns subscale

176

which measures concerns about prescribed medication. Score range for each scale is 0-25,

177

with higher scores reflecting stronger beliefs. The Pain Self-Efficacy Questionnaire (PSEQ)

178

was administered to assess participants’ perceived capacity to perform activities (e.g.,

179

household chores) while in pain and without medication (30), with higher scores (range 0-60)

180

reflecting higher self-efficacy beliefs. The Medical Outcomes Survey (MOS) Social Support

181

index assessed functional support from others; an average score was calculated (range 1-5),

182

with higher scores indicating greater support. Past 12 month use of alcohol, tobacco, and

183

cannabis was also assessed via single self-report items (yes/no).

184
185

Data Analysis

186

Participants were grouped by postcode in accordance with the 2006 edition of the Australian

187

Standard Geographical Classification (ASGC) (31) and grouped into three categories based

188

on remoteness of the community of residence: (i) major cities (‘Major City group’: 49%,

189

n=608), (ii) inner regional communities (‘Inner Regional group’: 37%, n=451), and (iii) outer

190

regional, remote and very remote communities (‘Outer Regional/Remote group’: 14%,

191

n=176). Although this sample was not intended to be nationally representative, as of June

192

2014, 71% of the Australian population resided in major cities, 18% in inner regional areas,

193

and 11% resided in outer regional, remote and very remote locations (32). Participants were

194

recruited from each state and territory in Australia (Queensland: 33%, n=408; New South

195

Wales: 22% n=267; Victoria: 19%, n=234; South Australia: 14%, n=167; Western Australia:
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7%, n=90; Tasmania: 4%, n=52; Australian Capital Territory: 1%, n=9; Northern Territory:

197

1%, n=8).

198
199

Data were analysed using multinomial logistic regression conducted in SPSS Statistics v21

200

(33); the referent category was the ‘Major City group’. Results are presented as relative risk

201

ratios (RRR; i.e., the probability of an outcome in one group relative to another).

202

Additionally, relative risk ratios were calculated to compare the ‘Inner Regional group’ and

203

‘Outer Regional/Remote group’ in regards to perceived barriers given that these outcomes

204

comprised the primary focus of the study. Percentages with 95% confidence intervals

205

(95%CI) are reported for categorical outcomes, means and standard deviations (M, SD) are

206

reported where continuous data were normally distributed, and medians and inter-quartile

207

ranges (M, IQR) are reported where continuous data show significant skew and/or kurtosis.

208

Adjusted RRR were calculated for health service access; barriers to treatment; medication

209

beliefs; pain self-efficacy; social support; and alcohol and other drug use outcomes. These

210

analyses controlled for age and sex (identified from research showing differences in pain

211

responses based on these characteristics; 34), low income (<AUD$400) and private health

212

insurance, and demographic and clinical variables statistically significant in univariate

213

analyses.

214
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Results

216

Sample Characteristics

217

The sample (n=1,235) had a median age of 59 (IQR: 49-68) and over half (57%) were female

218

(Table 1). The majority had not completed tertiary education (64%), reported income

219

<AUD$400 (59%), and did not have private health insurance (63%), and nearly half (47%)

220

were currently unemployed. The most common CNCP conditions reported by the sample

221

were chronic neck/back problems (79%), followed by arthritis/rheumatism (68%), and

222

frequent/severe headaches (45%) (Table 1). Participants reported being in pain for a median

223

of 10 years and had been taking pharmaceutical opioids for CNCP for a median period of 4

224

years.

225
226

Differences by Geographical Remoteness

227

Demographic Characteristics

228

Compared to the ‘Major City group’, participants in the ‘Inner Regional group’ and ‘Outer

229

Regional/Remote group’ had greater relative risk of being male and not have private health

230

insurance (Table 1). Further, the ‘Inner Regional group’ also reported poorer educational

231

attainment, and the Outer Regional/Remote group’ were more likely to be younger, than the

232

‘Major City group’.
***Table 1 approximately here***

233
234
235

Clinical Characteristics

236

The duration of living with CNCP and the rate of various CNCP conditions were similar

237

across the geographical remoteness groups (Table 1). The ‘Inner Regional group’ reported

238

lower BPI Severity scores, had better mental functioning and wellbeing (as scored on the SF-

239

12), and tended to report lower relative risk of exceeding PHQ-9 and GAD-7 score cut-offs
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indicative of current moderate-to-severe depression and anxiety respectively, compared to the

241

‘Major City group’.

242
243

Medication Use

244

Univariate analyses showed that the groups were similar in regards to length of time in opioid

245

treatment (4 years on average), median opioid dose, and in the distribution of persons

246

receiving a high OME daily dose (15% of the sample ≥200mg/day) (Table 1). The ‘Inner

247

Regional group’ had greater relative risk of currently using fentanyl and lower relative risk of

248

using oxycodone and prescription codeine in the past month, and the ‘Outer Regional/Remote

249

group’ had greater relative risk of using morphine in the past month, as compared to the

250

‘Major City group’.

251
252

Health Service Access

253

The majority of the sample had seen a GP in the past month (95%) on a median of two

254

occasions, with no significant difference between the geographical remoteness groups in the

255

number of visits (Table 2). Rates of past month ambulance and emergency department

256

access, and hospital-based day procedures were also similar across the remoteness groups;

257

past month use was 7%, 12%, and 11% of the total sample for each service, respectively. As

258

compared to the ‘Major City group’, the ‘Inner Regional group’ had a lower relative risk of

259

accessing physiotherapy and mental health services for chronic pain in the past month; these

260

associations were not statistically significant following multivariate analyses. The ‘Inner

261

Regional group’ and ‘Outer Regional/Remote group’ had two- and three-fold increased

262

relative risk of reporting past month use of other physical therapies as compared to the

263

‘Major City group’ (9% and 15% versus 5%); these associations remained statistically
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significant after adjusting for age, sex, income <AUD$400, private health insurance, tertiary

265

education and BPI Severity score.
***Table 2 approximately here***

266
267
268

Perceived Barriers to Health Service Access

269

As compared to the ‘Major City group’, the ‘Outer Regional/Remote group’ had significantly

270

a greater relative risk of reporting that they: i) felt their doctor was not confident in

271

prescribing pharmaceutical opioids, ii) had communication difficulties with their doctor, iii)

272

were unable to access specialist services, and iv) were unable to afford opioid medication

273

(Table 2). After adjusting for age, sex, income <AUD$400, private health insurance, tertiary

274

education and BPI Severity score, these associations remained significant with the exception

275

of ‘being unable to afford opioid medication’. There were no significant differences between

276

the ‘Major City group’ and the ‘Inner Regional group’ after adjustment for confounding

277

variables.

278
279

Calculation of relative risk (RR) to compare the ‘Inner Regional group’ and ‘Outer

280

Regional/Remote group’ showed that the latter were more likely to report that that they: i) felt

281

their doctor was not confident in prescribing pharmaceutical opioids (RR=1.24, 95%CI 1.07-

282

1.45), ii) had communication difficulties with their doctor (RR=1.22, 95%CI 1.05-1.43), iii)

283

felt their doctor was not listening or did not understand their condition (RR=1.14, 95%CI

284

1.00-1.31), iv) felt their doctor knew little about pain (RR=1.20, 95%CI 1.02-1.42), v) were

285

afraid they might become dependent on opioids (RR=1.13, 95%CI 1.01-1.26), vi) were

286

unable to access specialists (RR=1.17, 95%CI 1.01-1.35), and vii) were unable to afford

287

medication (RR=1.22, 95%CI 1.01-1.46).

288
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Medication Beliefs, Pain Self-Efficacy, Social Support and Alcohol and other Drug Use

290

In regards to medication beliefs, the ‘Outer Regional/Remote group’ scored significantly

291

higher on the Specific-Concerns BMQ subscale compared to the ‘Major City group’ however

292

this association was not statistically significant following adjustment for covariates (Table 3).

293

The ‘Inner Regional group’ scored higher on PSEQ and MOS Social Support score

294

(indicating greater pain self-efficacy and social support) as compared to the ‘Major City

295

group’; these associations remained statistically significant in multivariate analyses. Notably,

296

the ‘Outer Regional/Remote group’ also reported higher mean PSEQ scores compared to the

297

‘Major City group’ following adjustment for covariates. The ‘Inner Regional group’ reported

298

a greater relative risk of weekly or more frequent alcohol use in the past year, and the ‘Outer

299

Regional/Remote group’ reported a greater relative risk of weekly or more frequent cannabis

300

use, as compared to the ‘Major City group’; these associations were not statistically

301

significant in multivariate analyses.

302

***Table 3 approximately here***
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Discussion

304

Considerable effort has been dedicated to improving health care access for Australians in

305

regional and remote areas, including the National Strategic Framework for Rural and Remote

306

Health (35). This study represents the first detailed examination of remoteness differences in

307

access and barriers to health service use for chronic pain in Australia, a critical undertaking

308

given the increasing prevalence of CNCP and associated health care burden (2).

309
310

In regards to demographic and clinical profile, the ‘Inner Regional group’ and ‘Outer

311

Regional/Remote group’ were more likely to be male and have no private health insurance

312

than the ‘Major City group’; the latter group was also younger than the ‘Major City group’.

313

These findings align with national data showing that private health insurance (i.e., additional

314

healthcare cover to that provided by the Australian government Medicare scheme which is

315

paid for by the individual) is less common amongst residents of high socio-economic

316

disadvantage areas (as generally typified in regional and remote areas), with expense cited as

317

the primary barrier (36). Literature points to greater disadvantage in regional and remote

318

areas, evident via lower incomes (although this finding was not evident in the present study),

319

higher unemployment rates, and shorter life expectancies (16, 37). While the number of

320

people in the current study reporting low income and unemployment did not vary by

321

geographical remoteness, these indicators of disadvantage were considerably higher in this

322

sample overall than reported in the general population (38, 39). Similarly, poor mental and

323

physical health outcomes were elevated overall but generally did not differ significantly

324

across the remoteness groups (with the exception of better mental health outcomes for the

325

‘Inner Regional group’ relative to the ‘Major City group’). These findings suggest that

326

people with CNCP as a group may be characteristed by poorer socio-economic, mental and

327

physical wellbeing.
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329

In regards to treatment, the ‘Inner Regional group’ were more likely to be prescribed fentanyl

330

and less likely to be prescribed oxycodone and prescription codeine, and the ‘Outer

331

Regional/Remote group’ were more likely to be prescribed morphine, compared to the

332

‘Major City group’ though, despite the difference in prescribing patterns, no difference in

333

dose (represented as OME) was detected. Health service access generally did not differ

334

between the remoteness groups and perceived barriers to health service access were similar

335

for the ‘Major City group’ and ‘Inner Regional group’ (although the latter reported greater

336

pain self-efficacy and social support). In contrast, the ‘Outer Regional/Remote group’ were

337

more likely to report communication problems and lack of confidence in their doctor in

338

treating CNCP, difficulties accessing specialists, and difficulties affording opioid medication

339

(as well as higher pain self-efficacy), relative to both groups.

340
341

These perceived barriers reflect those reported in a study of people with chronic low back

342

pain in rural Western Australia, with patients citing poor access to information and sevices

343

and inadequate pain management training for local practitioners (18). Several population-

344

based studies have shown similar rates of health service access across urban and rural areas

345

with certain exceptions, including poorer specialist access in remote areas (17, 40-42).

346

Indeed, a systematic survey of 57 Australian services providing outpatient care for persistent

347

pain showed lower provision of pain specialist services for remote patients (14). However, it

348

important to note that these studies were conducted prior to, or initially following,

349

introduction of Australia’s National Pain Strategy (NPS). The NPS details strategic actions to

350

improve access to information and services, with an emphasis on skilled professionals,

351

evidence-based care, and interdisciplinary pain management (15, 43). Since then, a number of

352

initiatives have been implemented (43), including state-based pain management plans in New
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South Wales and Queensland, the Australian Government Medicare-based telehealth program

354

(i.e., support for patient-specialist video consultations), and 14 new regional pain centres (43,

355

44). Particular emphasis has been placed on training for general practitioners (45) in regional

356

and remote areas given that approximately one-fifth of patients seen in general practice report

357

chronic pain (46). While these endeavours must be acknowledged, the present results indicate

358

that continued efforts are required to address geographic inequality in treatment given the

359

perceived barriers reported by our participants. Indeed, preliminary evidence that certain pain

360

education programs for general health care providers (47) and patients (48) in remote areas in

361

Australia enhance practitioner skills, reduce waitlists, and decrease treatment costs is

362

promising for addressing patient-practitioner communication problems and patient

363

confidence in pain treatment.

364
365

Strengths and Limitations

366

The POINT cohort comprises the largest sample of people with CNCP interviewed in

367

Australia, with a wealth of data regarding a range of domains, particularly physical and

368

mental health, treatment, and health service access (19). Cohort participants were receiving

369

opioid therapy and recruited through pharmacies; thus, some similiarities in health care

370

access and perception of barriers across geographic area are to be expected in the present

371

study. This sample may not be representative of all people who are prescribed opioids for

372

CNCP. It may be that those people with barriers so significant that they cannot even access a

373

prescriber and/or pharmacy may not have been represented in this cohort. However, we have

374

previously compared key characteristics (gender, age and type of opioid) of those enrolled in

375

the study with the characteristics of all customers recorded as purchasing opioids in a random

376

sample of 71 recruiting pharmacies and found striking similarities (49). Specifically, 52%

377

were female (the POINT cohort was 55% female); and 7% were 18-34 years, 55% 35-64
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years and 38% 65+ years (vs. 5%, 62% and 33% respectively, in the POINT cohort). Of these

379

customers, 63% were prescribed oxycodone (vs. 62% in the POINT sample), 16.5%

380

prescribed morphine (vs. 15% in the POINT cohort), 21% prescribed fentanyl patches (vs.

381

15% in the POINT cohort) and 24% prescribed buprenorphine patches (vs. 21% in the

382

POINT cohort). Although it is not possible to determine whether all the opioid customers

383

recorded by these pharmacists had been taking these opioids for chronic pain, and for six

384

weeks or more, the similarities are reassuring. It should be noted a similar geographical

385

breakdown was evident for those participants who were excluded who had provided a

386

postcode (‘major cities’: 51%; inner regional: 36%; outer regional: 13%) to the final sample

387

used in the present study. It should be noted that those participants excluded due to not

388

completing core measures relevant to this study were more likely to be male (51% versus

389

43%, respectively) and younger (M=53.6 years, SD=13.5 versus M=58.4 years, SD=13.5)

390

than the final cohort. There are potential biases in self-report, although self-report is generally

391

reliable when there are no disincentives for being honest (50), and participants have been

392

assured of anonymity and confidentiality (as was the case in this study). The percentage of

393

the POINT cohort who reside in outer regional/remote areas is similar to that evident in the

394

general population (14% versus 11%, respectively) (32). However, given the number of

395

participants within the ‘Outer Regional/Remote group’, we would encourage consideration of

396

the effect size alongside statistical significance for comparisons involving this group given

397

reduced statistical power, and caution in drawing inferences from these analyses.

398
399

Conclusion

400

Despite similar self-reported rates of health service access, participants in outer regional and

401

remote areas were more likely to cite communication problems and lack of confidence in

402

their doctor in treating CNCP, difficulties accessing specialists, and difficulties affording
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403

opioid medication. In order to achieve “knowledgeable, empowered, and supported

404

consumers” of services (Goal 2 of the Australian National Pain Strategy; 15), future strategies

405

must be focused on enhancing the patient experience of treatment and maximising skills and

406

knowledge training amongst health care providers, with a focus on strategies targeted for

407

regional and remote locations.
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Table 1
Demographic and Clinical Characteristics of People with CNCP According to Geographical Remoteness

Outcomea

Demographics:
Age (M, IQR)
Male
Not completed tertiary education
Unemployed
Weekly income <AUD$400
Do not have private health
insurance
Pain Condition:
Duration of living in pain
(months; M, IQR)
CNCP conditions (lifetime):
Chronic back/neck problems
Arthritis/ rheumatism
Frequent/severe headaches
Visceral pain
Brief Pain Inventory (BPI):
Severity score (M, SD)
Brief Pain Inventory (BPI):
Interference score (M, SD)
Health:
Short Form Health Survey (SF12): Mental Health score (M, SD)
Short Form Health Survey (SF12): Physical Health score (M,

Total
Sample
(n=1,235)

(A)
Major City
group
n=608

(B)
Inner Regional
Group
n=627

(C)
Outer Regional/Remote
group
n=176

%
(95% CI)

%
(95% CI)

%
(95% CI)

59 (49-68)
43 (40-46)
64 (61-67)
47 (44-50)
59 (56-62)

59 (48-69)
39 (35-42)
61 (57-64)
48 (44-520
57 (53-61)

63 (60-66)

B vs A (ref) b

C vs A (ref) b

%
(95% CI)

RRR (95% CI)
p value

RRR (95% CI)
p value

60 (50-68)
46 (42-51)
69 (64-73)
43 (38-47)
62 (34-43)

57 (47-65)
50 (43-57)
64 (56-70)
52 (44-59)
59 (52-65)

1.01 (1.00-1.01), p=.289
1.38 (1.08-1.77), p=.010
1.43 (1.11-1.85), p=.006
0.79 (0.62-1.01), p=.062
1.24 (0.97-1.59), p=.090

0.98 (0.97-1.00), p=.014
1.60 (1.14-2.24), p=.006
1.14 (0.81-1.62), p=.456
1.14 (0.82-1.60), p=.434
1.08 (0.77-1.52), p=.646

58 (54-62)

68 (63-72)

69 (62-76)

1.53 (1.19-1.97), p=.001

1.65 (1.16-2.37), p=.006

120 (60252)

120 (48-264)

144 (60-276)

120 (60-204)

1.00 (1.00-1.00), p=0.573

1.00 (1.00-1.00), p=.870

69 (77-82)
68 (66-71)
45 (42-48)
31 (29-34)

80 (77-83)
68 (64-71)
46 (42-50)
32 (28-36)

79 (75-83)
71 (66-75)
43 (38-47)
32 (28-36)

77 (71-83)
64 (56-70)
46 (39-53)
29 (23-36)

0.94 (0.70-1.28), p=.707
1.14 (0.87-1.48), p=.340
0.89 (0.70-1.14), p=.343
0.99 (0.76-1.29), p=.945

0.85 (0.56-1.27), p=.414
0.83 (0.59-1.18), p=.306
1.01 (0.72-1.42), p=.944
0.87 (0.60-1.26), p=.460

5.0 (1.8)

5.2 (1.8)

4.9 (1.8)

5.0 (1.7)

0.92 (0.86-0.98), p=.012

0.96 (0.87-1.05), p=.329

5.9 (2.3)

5.7 (2.3)

5.4 (2.3)

5.7 (2.2)

0.95 (0.91-1.01), p=.088

1.00 (0.92-1.07), p=.900

44.3 (33.254.7)
26.5 (22.331.3)

41.8 (32.054.0)
26.2 (21.930.8)

46.9 (35.0-55.7)

45.4 (34.7-54.6)

1.02 (1.01-1.03), p=.002

1.01 (1.00-1.02), p=.160

26.7 (22.7-31.4)

26.4 (23.1-32.07)

1.01 (0.99-1.03), p=.201

1.01 (0.99-1.03), p=.413

SD)
Depression (PHQ-9 score ≥10)
Anxiety (GAD-7 score ≥10) ^
PTSD (Primary Care PTSD
Screen score ≥3)
Medication Use:
Median OME daily dose (mg; M,
IQR)
OME daily dose >200mg^
Duration continuous opioid
medication (months; M, IQR)
Current prescribed
opioid medication:
Oxycodone
Morphine
Buprenorphine
Methadone
Fentanyl
Tramadol
Hydromorphone
Prescription codeine

44 (42-47)
22 (20-24)

48 (44-52)
23 (20-27)

40 (35-44)
17 (14-21)

44 (37-52)
27 (21-34)

0.71 (0.55-0.90), p=.006
0.69 (0.50-0.95), p=.021

0.86 (0.61-1.20), p=.376
1.24 (0.84-1.82), p=.279

14 (13-16)

16 (13-19)

12 (9-15)

15 (11-21)

0.73 (0.51-1.04), p=.079

0.97 (0.61-1.54), p=.885

73 (36-144)

76 (36-150)

68 (35-126)

66 (31-144)

1.00 (1.00-1.00), p=.124

1.00 (1.00-1.00), p=.793

15 (13-17)

16 (13-19)

12 (10-16)

19 (14-26)

0.75 (0.52-1.10), p=.137

1.25 (0.79-1.98), p=.349

48 (18-120)

48 (24-120)

48 (16-120)

60 (40-132)

1.01 (1.00-1.00), p=.317

1.01 (1.00-1.00), p=.216

60 (57-63)
15 (14-18)
23 (20-25)
4 (3-5)
14 (13-17)
10 (8-11)
4 (3-5)
23 (21-26)

63 (59-67)
16 (13-19)
21 (18-25)
4 (3-6)
13 (10-15)
10 (8-13)
4 (3-6)
26 (22-29)

56 (52-61)
12 (10-16)
25 (21-29)
4 (2-6)
18 (15-22)
8 (6-11)
4 (2-6)
19 (16-23)

60 (52-67)
22 (17-29)
22 (16-28)
6 (3-10)
13 (8-18)
11 (8-17)
3 (1-7)
25 (19-32)

0.76 (0.60-0.98), p=.033
0.74 (0.52-1.06), p=.099
1.24 (0.93-1.66), p=.142
0.94 (0.49-1.79), p=.841
1.51 (1.07-2.12), p=.018
0.73 (0.47-1.12), p=.150
1.00 (0.53-1.89), p=.991
0.70 (0.52-0.94), p=.018

0.88 (0.62-1.23), p=.445
1.52 (1.00-2.30), p=.049
1.02 (0.68-1.54), p=.915
1.53 (0.72-3.28), p=.269
1.00 (0.60-1.66), p>.999
1.11 (0.65-1.89), p=.704
0.74 (0.28-1.99), p=.555
0.97 (0.66-1.43), p=.895

Note. ^48 participants had missing data for GAD-7 and only 1094 participants provided data to calculate OME. OME: oral morphine equivalent.
PHQ-9: Patient Health Questionnaire; GAD-7: Generalised Anxiety Disorder scale; PTSD: post-traumatic stress disorder; RRR: relative risk
ratio; 95% CI: 95% confidence interval; M, IQR: median and IQR: interquartile range; M, SD: mean and standard deviation. Bolded values
indicate statistical significance (p<.050); italicised variables indicate trend towards statistical significance (p<.100).

Table 2
Health Service Access and Perceived Barriers to Access for People with CNCP According to Geographical Remoteness

Outcome

Service Use (past
month)
General Practitioner
Number of visits
amongst those who
had accessed GP
(M, IQR)
Ambulance
Emergency
Department
Day Procedure
Physiotherapy #
Mental Health
Services#
Specialist Services#
Physical Therapies#
Complementary and

Total
Sample
n=1,235

(A)
Major
City
group
n=608

(B)
Inner
Regional
group
n=451

(C)
Outer
Regional/Remote
group
n=176

%
(95%
CI)

%
(95%
CI)

%
(95% CI)

%
(95% CI)

95 (9496)

96 (9598)

94 (92-96)

2 (1-3)

2 (1-3)

7 (5-8)
12 (1014)

B vs A (ref)

C vs A (ref)

B vs A (ref)

C vs A (ref)

RRR
(95% CI)
p value

RRR
(95% CI)
p value

Adjusted RRR
(95% CI)
p value

Adjusted RRR
(95% CI)
p value

94 (89-97)

0.61 (0.34-1.09),
p=.097

0.56 (0.27-1.19),
p=.130

0.66 (0.36-1.21),
p=.178

0.55 (0.26-1.17),
p=.121

2 (1-2)

2 (1-3)

0.97 (0.89-1.05),
p=.391

1.01 (0.91-1.11),
p=.879

0.99 (0.91-1.07),
p=.713

1.00 (0.91-1.11),
p=.941

7 (5-10)

7 (5-9)

5 (3-9)

11 (9-14)

13 (10-16)

14 (9-20)

9 (7-12)

9 (6-14)

13 (10-16)

19 (14-26)

9 (6-12)

10 (7-16)

12 (10-16)

12 (8-18)

0.89 (0.55-1.44),
p=.622
1.17 (0.81-1.71),
p=.403
0.70 (0.46-1.04),
p=.078
0.69 (0.49-0.98),
p=.035
0.66 (0.44-1.00),
p=.046
0.71 (0.50-1.02),
p=.059
1.65 (1.02-2.67),
p=.041
0.94 (0.74-1.21),

0.69 (0.33-1.44),
p=.326
1.28 (0.77-2.10),
p=.341
0.71 (0.40-1.25),
p=.238
1.13 (0.74-1.74),
p=.566
0.80 (0.46-1.37),
p=.414
0.68 (0.41-1.26),
p=.131
3.02 (1.75-5.21),
p<.001
0.92 (0.66-1.30),

0.86 (0.52-1.44),
p=.577
1.11 (0.75-1.64),
p=.606
0.70 (0.46-1.06),
p=.090
0.83 (0.57-1.19),
p=.308
0.74 (0.48-1.14),
p=.172
0.81 (0.56-1.18),
p=.273
1.66 (1.02-2.70),
p=.042
0.98 (0.76-1.27),

0.71 (0.34-1.51),
p=.712
1.16 (0.69-1.94),
p=.571
0.75 (0.42-1.33),
p=.324
1.39 (0.89-2.17),
p=.155
0.70 (0.39-1.23),
p=.213
0.73 (0.43-1.22),
p=.225
2.92 (1.67-5.08),
p<.001
0.96 (0.67-1.37),

14 (1216)

12 (1015)
17 (1521)
13 (1015)
17 (1420)

8 (7-10)

5 (4-8)

9 (6-12)

15 (10-21)

42 (39-

42 (38-

41 (36-45)

40 (33-48)

11 (9-13)
16 (1418)
11 (9-13)

Alternative Therapies#
Barriers to Access
Felt your doctor was
not confident in
prescribing drugs for
pain treatment
Experienced
communication
problems with your
doctor
Felt your doctor was
not
listening/understanding
Felt your doctor knew
little about pain
Fear you may become
dependent on drugs
Felt your doctor would
consider your drugseeking
Unable to get to a
pharmacy or doctor
Unable to access
specialist advice
Unable to afford opioid
medication
Unable to afford other
types of medication
Unable to afford other
treatments
(e.g., counselling,
physiotherapy)

44)

46)

p=.631

p=.648

p=.885

p=.960

19 (1721)

18 (1522)

16 (13-20)

28 (21-35)

0.86 (0.62-1.20),
p=.379

1.71 (1.15-2.54),
p=.008

0.96 (0.58-1.36),
p=.816

1.73 (1.14-2.62),
p=.009

19 (1621)

19 (1622)

15 (12-19)

25 (20-32)

0.79 (0.57-1.09),
p=.152

1.48 (0.99-2.20),
p=.055

0.87 (0.61-1.23),
p=.427

1.47 (0.96-2.23),
p=.075

20 (1822)

19 (1622)

19 (15-22)

26 (20-33)

0.98 (0.72-1.35),
p=.913

1.53 (1.03-2.28),
p=.036

1.12 (0.80-1.56),
p=.518

1.57 (1.03-2.37),
p=.035

15 (1317)
37 (3540)
11 (9-13)

15 (1218)
40 (3644)
11 (9-14)

13 (10-16)

21 (16-28)

32 (28-36)

42 (34-49)

9 (7-12)

15 (10-21)

0.84 (0.59-1.19),
p=.322
0.71 (0.55-0.91),
p=.008
0.78 (0.52-1.18),
p=.241

1.49 (0.97-2.29),
p=.069
1.07 (0.76-1.51),
p=.697
1.33 (0.81-2.17),
p=.263

0.98 (0.67-1.42),
p=.902
0.79 (0.60-1.03),
p=.081
0.88 (0.57-1.35),
p=.543

1.56 (0.99-2.45),
p=.055
1.12 (0.78-1.60),
p=.536
1.28 (0.76-2.14),
p=.357

15 (1317)
19 (1621)
12 (1114)
21 (1923)
41 (3843)

15 (1318)
18 (1521)
12 (1015)
21 (1825)
40 (3745)

13 (10-16)

18 (13-25)

17 (14-21)

26 (20-33)

11 (8-14)

18 (13-24)

19 (15-23)

26 (20-33)

40 (36-45)

42 (35-49)

0.81 (0.57-1.16),
p=.256
0.97 (0.71-1.35),
p=.872
0.87 (0.59-1.29),
p=.498
0.84 (0.62-1.14),
p=.267
0.99 (0.77-1.27),
p=.942

1.25 (0.80-1.95),
p=.334
1.62 (1.08-2.42),
p=.019
1.61 (1.01-2.55),
p=.044
1.26 (0.85-1.87),
p=.247
1.06 (0.75-1.50),
p=.749

0.94 (0.64-1.39),
p=.759
1.10 (0.77-1.55),
p=.606
0.90 (0.60-1.35),
p=.613
0.86 (0.62-1.19),
p=.354
1.06 (0.80-1.39),
p=.703

1.16 (0.72-1.88),
p=.548
1.56 (1.01-2.39),
p=.044
1.40 (0.87-2.28),
p=.170
1.11 (0.73-1.67),
p=.639
0.95 (0.65-1.38),
p=.783

Note. Adjusted analyses (AOR) control for age, sex, current private health insurance, income<$400AUD, tertiary education, and BPI pain
severity score. # Note that this data refers only to use of services specifically for pain treatment. RRR: relative risk ratio; 95% CI: 95%
confidence interval; M: median; IQR: interquartile range. Bolded values indicate statistical significance (p<.050).

Table 3
Medication Beliefs, Pain Self-Efficacy, Social Support and Alcohol and other Drug Use According to Geographical Remoteness

Total Sample
n=1,235

(A)
Major City
group
n=608

(B)
Inner
Regional
group
n=451

(C)
Outer
Regional/Rem
ote group
n=176

%
(95% CI)

%
(95% CI)

%
(95% CI)

%
(95% CI)

Medication Beliefs:
Specific-Necessity (M, SD)
Medication Beliefs:
Specific-Concerns (M, SD)
Coping and Support:

19.8 (3.8)

19.5 (3.8)

19.8 (3.8)

20.1 (3.5)

14.2 (4.3)

13.8 (4.2)

14.2 (4.5)

14.8 (4.1)

Pain Self Efficacy
Questionnaire (PSEQ) score
(M, SD)
Medical Outcomes Survey
(MOS) Social Support score
(M, SD)
Alcohol and Drug Use:

29.9 (13.4)

28.5 (13.5)

31.5 (13.1)

3.3 (1.1)

3.2 (1.1)

Used alcohol weekly or
more frequent (past 12
month)
Used tobacco daily or more
frequently (past 12 months

29 (27-32)

31 (28-33)

Outcomea

B vs A (ref)

C vs A (ref)

B vs A (ref)

C vs A (ref)

RRR (95%
CI)
p value

RRR (95%
CI)
p value

Adjusted
RRR (95%
CI)
p value

Adjusted
RRR (95%
CI)
p value

1.02 (0.981.07), p=.374
1.02 (0.981.06), p=.253

1.04 (0.981.10), p=.189
1.05 (1.001.11), p=.039

1.01 (0.971.06), p=.647
1.03 (0.981.07), p=.231

1.04 (0.981.11), p=.173
1.05 (1.001.11), p=.061

30.2 (13.6)

1.02 (1.011.03), p=.001

1.01 (1.001.02), p=.153

1.02 (1.011.03), p=.001

1.02 (1.001.03), p=.025

3.3 (1.1)

3.3 (1.1)

1.12 (1.011.26), p=.041

1.08 (0.931.26), p=.335

1.13 (1.001.27), p=.044

1.12 (0.961.32), p=.155

27 (23-30)

33 (29-37)

29 (23-36)

1.34 (1.021.75), p=.033

1.11 (0.771.62), p=.579

1.33 (1.001.76), p=.051

1.14 (0.771.68), p=.522

31 (28-35)

28 (24-33)

33 (27-41)

0.86 (0.651.12), p=.251

1.09 (0.761.56), p=.630

0.76 (0.561.03), p=.079

0.79 (0.531.18), p=.253

Medication Beliefs:

month)
Used cannabis weekly or
more frequently (past 12
months)

6 (5-8)

6 (4-8)

5 (3-7)

10 (7-16)

0.78 (0.451.35), p=.372

1.81 (1.003.28), p=.049

0.62 (0.351.11), p=.104

1.19 (0.642.23), p=.589

Note. Adjusted analyses (AOR) control for age, sex, current private health insurance, income<$400AUD, tertiary education, and BPI pain
severity score. RRR: relative risk ratio; 95% CI: 95% confidence interval; M, SD: mean and standard deviation. Bolded values indicate statistical
significance (p<.050).

